EUROIMMUN→PerkinElmer (Revvity)
Acquisition · Cash · announced Jun 16, 2017
Announced
Jun 16, 2017
Closed
Dec 19, 2017
Economics
Cash()
Pre-deal · pre-deal mark: 2017, year precision · rounding grid ±$100M · PerkinElmer 8-K filing, SEC EDGAR — EUROIMMUN acquisition
~$1.3B cash
Target
EUROIMMUN
Diagnostics · Diagnostic / genomic
HQ Lübeck, Germany · Founded 1987
Global leader in autoimmune diagnostics — extensive immunology, cell biology, and molecular biology capabilities; reproductive health channel drives into US market
- SEC EDGAR — PerkinElmer 8-K (Jun 16, 2017)
- GenomeWeb — deal coverage (Jun 19, 2017)
- Revvity (PerkinElmer) investor relations — completion (Dec 19, 2017)
Acquirer
PerkinElmer (Revvity)
Healthcare
HQ Waltham, MA
Life sciences and diagnostics company — reproductive health, newborn screening, autoimmune diagnostics; rebranded diagnostics business as Revvity (2023)
Why this buyer
Curated copy from the verified dataset — not an 8-K LLM summary
Global autoimmune diagnostics leader — drives EUROIMMUN's capabilities into PerkinElmer's US reproductive health channel; 19% revenue CAGR; operations in 130+ countries with 45% revenue from China
Evidence ladder
Primary (regulatory / filing)
SEC EDGAR — PerkinElmer 8-K (Jun 16, 2017)
Tertiary (trade / analyst)
Revvity investor relations — completion (Dec 19, 2017)
Primary (regulatory / filing)
SEC EDGAR 8-K https://www.sec.gov/Archives/edgar/data/31791/000119312517206411/d410886d8k.htm
Open source
Limitations
- ~$1.3B cash
- Pre-deal valuation sourced from: PerkinElmer 8-K filing, SEC EDGAR — EUROIMMUN acquisition. Pre-deal market-cap and funding citations do not corroborate the acquisition.
Valuation peers · Diagnostics
Same sector, same deal type, announced within ±3 years, disclosed value within 0.25×–4× of this transaction. Ranked by evidence class, then same acquirer.
| Target | Acquirer | Announced | Value | Why included |
|---|---|---|---|---|
| Counsyl | Myriad Genetics | May 28, 2018 | same evidence class | |
| Sequenom | LabCorp | Jul 27, 2016 | same evidence class | |
| Thrive Earlier Detection | Exact Sciences | Oct 27, 2020 | same evidence class |
Same-sector adjacency — not valuation peers
These deals share the sector tag and window but sit outside the 0.25×–4× value band. The dataset keeps them for clinical adjacency, not as price comps.
| Target | Acquirer | Announced | Value | Vs this deal |
|---|---|---|---|---|
| Alere | Abbott Laboratories | Feb 1, 2016 | ||
| nVision Medical | Boston Scientific | Apr 16, 2018 |
Patient empowerment context
Patient empowerment baseline (HLTH 2022)
No curated mapping — EUROIMMUN (Diagnostics). HLTH/Outcomes4Me 2022 baseline is Breast cancer care continuum (HLTH 2022). No curated mapping for this target in the verified crosswalk.
Research workspace (includes heuristic crosswalk) →Related verified workspaces
Lacuna is a curated public-source sample, not a census of women's-health M&A. Coverage varies by sector, geography, disclosure availability, and women's-health scope. Undisclosed transaction values are excluded from disclosed-value totals.
Curated verified dataset v9 · updated 2026-09-20 · 3 citations on this deal · Data compiled from public sources for educational visualization. Verify independently before any commercial use.